Business Description
Sudarshan Pharma Industries Ltd
ISIN : INE00TV01023
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.02 | |||||
Equity-to-Asset | 0.37 | |||||
Debt-to-Equity | 1.06 | |||||
Debt-to-EBITDA | 4.05 | |||||
Interest Coverage | 2.43 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 5.72 | |||||
Beneish M-Score | -2.23 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 33.8 | |||||
3-Year EBITDA Growth Rate | 50.3 | |||||
3-Year EPS without NRI Growth Rate | 62.5 | |||||
3-Year FCF Growth Rate | 15.1 | |||||
3-Year Book Growth Rate | -41.8 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 51.89 | |||||
9-Day RSI | 49.79 | |||||
14-Day RSI | 51.02 | |||||
6-1 Month Momentum % | 435.19 | |||||
12-1 Month Momentum % | 463.39 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.34 | |||||
Quick Ratio | 0.82 | |||||
Cash Ratio | 0.01 | |||||
Days Inventory | 79.25 | |||||
Days Sales Outstanding | 93.05 | |||||
Days Payable | 62.11 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -193.2 | |||||
Shareholder Yield % | -6.55 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 11.33 | |||||
Operating Margin % | 6.42 | |||||
Net Margin % | 2.73 | |||||
FCF Margin % | 6.93 | |||||
ROE % | 11.24 | |||||
ROA % | 4.33 | |||||
ROIC % | 10.27 | |||||
ROC (Joel Greenblatt) % | 16.11 | |||||
ROCE % | 23.42 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 80.39 | |||||
PE Ratio without NRI | 75.18 | |||||
PEG Ratio | 2.07 | |||||
PS Ratio | 2.2 | |||||
PB Ratio | 8.55 | |||||
Price-to-Tangible-Book | 8.81 | |||||
Price-to-Free-Cash-Flow | 31.62 | |||||
Price-to-Operating-Cash-Flow | 29.5 | |||||
EV-to-EBIT | 38.79 | |||||
EV-to-EBITDA | 36.59 | |||||
EV-to-Revenue | 2.44 | |||||
EV-to-FCF | 34.98 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.49 | |||||
Price-to-Graham-Number | 5.41 | |||||
Price-to-Net-Current-Asset-Value | 17.66 | |||||
Earnings Yield (Greenblatt) % | 2.57 | |||||
FCF Yield % | 3.19 | |||||
Forward Rate of Return (Yacktman) % | 18.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Sudarshan Pharma Industries Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ₹) | 4,595.333 | ||
EPS (TTM) (₹) | 0.52 | ||
Beta | 0 | ||
Volatility % | 147.22 | ||
14-Day RSI | 51.02 | ||
14-Day ATR (₹) | 1.423076 | ||
20-Day SMA (₹) | 41.884 | ||
12-1 Month Momentum % | 463.39 | ||
52-Week Range (₹) | 5.82 - 46 | ||
Shares Outstanding (Mil) | 240.66 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Sudarshan Pharma Industries Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Sudarshan Pharma Industries Ltd Stock Events
Event | Date | Price(₹) | ||
---|---|---|---|---|
No Event Data |
Sudarshan Pharma Industries Ltd Frequently Asked Questions
What is Sudarshan Pharma Industries Ltd(BOM:543828)'s stock price today?
When is next earnings date of Sudarshan Pharma Industries Ltd(BOM:543828)?
Does Sudarshan Pharma Industries Ltd(BOM:543828) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |